MAY 29, 2016 8:00 AM PDT

Anti-Xa for Monitoring Heparin

Sponsored by: Diagnostica Stago, Inc.
  • Clinical Pharmacist in the Commercial and Specialty Pharmacy Division, Florida Blue
      Keri is a Clinical Pharmacist in the Commercial and Specialty Pharmacy Division at Florida Blue where she primarily establishes and maintains medical coverage guidelines for specialty medications. Keri previously worked as an Assistant Professor in the Department of Pharmacy Practice at South University from 2010 to 2015. She coordinated and lectured in courses including Communications, Quality Improvement and Patient Safety, Professional Practice and Informatics, and Drug Information. She precepted residents and students in the Drug information center and established a clinical practice site for students in Internal Medicine at Southeast Georgia Regional Health System. Keri completed an ASHP accredited PGY1 residency at Shands Jacksonville and a PGY2 specialty residency in Drug Information at South University, with accompanying activities at Memorial University Medical Center, St. Joseph's/Candler Hospital, and NorthStar Healthcare Consulting. Prior to attending pharmacy school at South University, Keri worked as a software consultant in informatics for Cerner Corporation from 2001 to 2005. Keri is an active member of GSHP and serves as the Southeast District Director coordinating district meetings in the Savannah and St. Simons area. She previously served as co-chair of the GSHP Education Committee from 2011 to 2014. Keri is also a member of ACCP, ASHP, AACP, the American Cancer Society Victory Board, Auxiliary of Hospice of the Golden Isles, and the Golden Isles UGA Alumni Association.


    Anticoagulants are effective for prevention and treatment of prothrombotic disease states and can be prescribed for parenteral (IV) or oral administration.  Several novel, direct acting oral anticoagulants (abbreviated as NOACs or DOACs) have been introduced over the past few years.  A review of anticoagulant therapy approaches and indications will be provided along with recommended methods for monitoring and/or activity measurement; including a comprehensive discussion of how the different assay methods are affected by various pre-analytical, analytical, and biological states.

    • Compare traditional anticoagulants to novel oral anticoagulants (NOACs).
    • Discuss the differences between the NOACs.
    • Evaluate methods for monitoring traditional anticoagulants and measuring activity of NOACs.
    • Discuss potential anticoagulant assay interferences.

    Show Resources
    Show Resources
    • See more